Enobosarm
Sources
registry, as of 2026-09-04Stale
https://clinicaltrials.gov/study/NCT07446998
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Veru Inc.. Enrollment 239. Conditions Obesity & Overweight; Mobility Disability; HOMA-IR. The primary objective of this study is to assess the effect of enobosarm on total body weight
ClinicalTrials.gov NCT07446998 protocol and results modules
registry, as of 2025-09-17Stale
https://clinicaltrials.gov/study/NCT06282458
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt. Overall status COMPLETED. Phases PHASE2. Lead sponsor Veru Inc.. Enrollment 168. Conditions Muscle Loss; Obesity. The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
ClinicalTrials.gov NCT06282458 protocol and results modules
publication, as of 2024-03-04Stale
https://pubmed.ncbi.nlm.nih.gov/38342115/
suppressor in oestrogen receptor-positive breast cancer. The activity and safety of enobosarm, an oral selective androgen receptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and androgen receptor (AR)-positive disease. Women who were postmenopausal (aged ≥18 years) wi
PMID 38342115